Experimental validation of a fragment library for lead discovery using SPR biosensor technology

Journal of Biomolecular Screening

Volumn 16, Issue 1, 2011, Pages 15-25

  Elinder, Malin ^a   Geitmann, Matthis ^b   Gossas, Thomas ^b   Källblad, Per ^b   Winquist, Johan ^a   Nordström, Helena ^a   Hämäläinen, Markku ^c   Danielson, U Helena ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Beactica   (Sweden)

^c GE Healthcare Bio Sciences AB   (Sweden)

Author keywords

enzyme; fragment library; fragment screening; interaction analysis; SPR biosensor

Indexed keywords

CARBONATE DEHYDRATASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN SERUM ALBUMIN; THROMBIN;

ARTICLE; BIOSENSOR; ENZYME ANALYSIS; ENZYME STRUCTURE; MOLECULAR LIBRARY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

ANIMALS; BIOSENSING TECHNIQUES; CARBONIC ANHYDRASE II; CATTLE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIV PROTEASE; HUMANS; PROTEIN BINDING; SERUM ALBUMIN; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE; THROMBIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78951492035     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110389038     Document Type: Article

References (29)

1. Hajduk PJ, Greer J.: A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007 ; 6: 211-219.
2. Warr WA: Fragment-based drug discovery. J Comput Aided Mol Des 2009 ; 23: 453-458.
3. Perspicace S., Banner D., Benz J., Muller F., Schlatter D., Huber W.: Fragment-based screening using surface plasmon resonance technology. J Biomol Screen 2009 ; 14: 337-349.
4. Danielson UH: Fragment library screening and lead characterization using SPR biosensors. Curr Top Med Chem 2009 ; 9: 1725-1735.
5. Schuffenhauer A., Brown N., Selzer P., Ertl P., Jacoby E.: Relationships between molecular complexity, biological activity, and structural diversity. J Chem Inf Model 2006 ; 46: 525-535.
6. Hann MM, Leach AR, Harper G.: Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001 ; 41: 856-864.
7. Schuffenhauer A., Ruedisser S., Marzinzik AL, Jahnke W., Blommers M., Selzer P., Jacoby E.: Library design for fragment based screening. Curr Top Med Chem 2005 ; 5: 751-762.
8. Baurin N., Aboul-Ela F., Barril X., Davis B., Drysdale M., Dymock B.,, et al. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 2004 ; 44: 2157-2166.
9. Blomberg N., Cosgrove DA, Kenny PW, Kolmodin K.: Design of compound libraries for fragment screening. J Comput Aided Mol Des 2009.
10. Lipinski CA, Lombardo F., Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001 ; 46: 3-26.
11. Congreve M., Carr R., Murray C., Jhoti H.: A 'rule of three' for fragment-based lead discovery ? Drug Discov Today 2003 ; 8: 876-877.
12. Irwin JJ, Shoichet BK: ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005 ; 45: 177-182.
13. Danielson H., Lindgren MT, Markgren PO, Nillroth U.: Investigation of an allosteric site of HIV-1 proteinase involved in inhibition by Cu2+. Adv Exp Med Biol 1998 ; 436: 99-103.
14. Elinder M., Nordström H., Geitmann M., Hämäläinen M., Vrang L., Aberg B,, et al. Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants. J Biomol Screen 2009 ; 14: 395-403.
15. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
16. Hann MM, Oprea TI: Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004 ; 8: 255-263.
17. Teague SJ, Davis AM, Leeson PD, Oprea T.: The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 1999 ; 38: 3743-3748.
18. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD: Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002 ; 45: 2615-2623.
19. van De Waterbeemd H., Smith DA, Beaumont K., Walker DK: Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001 ; 44: 1313-1333.
20. Baurin N., Baker R., Richardson C., Chen I., Foloppe N., Potter A.,, et al. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J Chem Inf Comput Sci 2004 ; 44: 643-651.
21. Fejzo J., Lepre CA, Peng JW, Bemis GW, Ajay, Murcko MA,, et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol 1999 ; 6: 755-769.
22. Bemis GW, Murcko MA: The properties of known drugs: 1. Molecular frameworks. J Med Chem 1996 ; 39: 2887-2893.
23. Vieth M., Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA,, et al. Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 2004 ; 47: 224-232.
24. Broughton HB, Watson IA: Selection of heterocycles for drug design. J Mol Graph Model 2004 ; 23: 51-58.
25. Rishton GM: Reactive compounds and in vitro false positives in HTS. Drug Discov Today 1997 ; 2: 382-384.
26. Rishton GM: Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 2003 ; 8: 86-96.
27. Giannetti AM, Koch BD, Browner MF: Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J Med Chem 2008 ; 51: 574-580.
28. Davis TM, Wilson WD: Determination of the refractive index increments of small molecules for correction of surface plasmon resonance data. Anal Biochem 2000 ; 284: 348-353.
29. Christopeit T., Gossas T., Danielson UH: Characterization of Ca2+ and phosphocholine interactions with C-reactive protein using a surface plasmon resonance biosensor. Anal Biochem 2009 ; 391: 39-44.